L3 Update of the OpACIN and OpACIN-neo trials: 36-months...

Journal for ImmunoTherapy of Cancer 2020 / 10 Vol. 8; Iss. Suppl 2

L3 Update of the OpACIN and OpACIN-neo trials: 36-months and 24-months relapse-free survival after (neo)adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma patients

Versluis, JM, Rozeman, EA, Menzies, AM, Reijers, ILM, Krijgsman, O, Hoefsmit, EP, van de Wiel, BA, Sikorska, K, Bierman, C, Dimitriadis, P, Gonzalez, M, Broeks, A, Kerkhoven, RM, Spillane, AJ, Haanen,
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
8
Journal:
Journal for ImmunoTherapy of Cancer
DOI:
10.1136/jitc-2020-itoc7.3
Date:
October, 2020
File:
PDF, 57 KB
2020
Conversion to is in progress
Conversion to is failed